EA028434B1 - Лечение рака ингибиторами tor киназы - Google Patents

Лечение рака ингибиторами tor киназы Download PDF

Info

Publication number
EA028434B1
EA028434B1 EA201491694A EA201491694A EA028434B1 EA 028434 B1 EA028434 B1 EA 028434B1 EA 201491694 A EA201491694 A EA 201491694A EA 201491694 A EA201491694 A EA 201491694A EA 028434 B1 EA028434 B1 EA 028434B1
Authority
EA
Eurasian Patent Office
Prior art keywords
overexpression
patient
twenty
stereoisomer
ethyl
Prior art date
Application number
EA201491694A
Other languages
English (en)
Russian (ru)
Other versions
EA201491694A1 (ru
Inventor
Шуйчань Сюй
Кристен Мей Хедж
Original Assignee
СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of EA201491694A1 publication Critical patent/EA201491694A1/ru
Publication of EA028434B1 publication Critical patent/EA028434B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EA201491694A 2012-03-15 2013-03-14 Лечение рака ингибиторами tor киназы EA028434B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611370P 2012-03-15 2012-03-15
US201261715329P 2012-10-18 2012-10-18
PCT/US2013/031202 WO2013138556A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201491694A1 EA201491694A1 (ru) 2015-06-30
EA028434B1 true EA028434B1 (ru) 2017-11-30

Family

ID=47998542

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491694A EA028434B1 (ru) 2012-03-15 2013-03-14 Лечение рака ингибиторами tor киназы

Country Status (20)

Country Link
US (1) US20130245029A1 (https=)
EP (1) EP2825168B1 (https=)
JP (2) JP2015516375A (https=)
KR (3) KR20190058673A (https=)
CN (2) CN107137402A (https=)
AU (1) AU2013203156C1 (https=)
BR (1) BR112014022697A2 (https=)
CA (1) CA2867349A1 (https=)
EA (1) EA028434B1 (https=)
ES (1) ES2677908T3 (https=)
IL (2) IL234640B (https=)
MX (1) MX360877B (https=)
MY (1) MY182650A (https=)
NI (1) NI201400109A (https=)
NZ (1) NZ628421A (https=)
PH (2) PH12014502048B1 (https=)
SG (1) SG11201405706TA (https=)
TW (2) TWI664968B (https=)
WO (1) WO2013138556A1 (https=)
ZA (1) ZA201406709B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
US9937169B2 (en) 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
TW201527300A (zh) 2013-04-17 2015-07-16 Signal Pharm Llc 關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－三唑－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法
BR112015026297B1 (pt) 2013-04-17 2022-08-23 Signal Pharmaceuticals, Llc Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit
US9782427B2 (en) 2013-04-17 2017-10-10 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
BR112015026292B1 (pt) 2013-04-17 2022-04-12 Signal Pharmaceuticals, Llc Uso de 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il)-3,4-dihidropirazino [2,3-b]pirazin-2(1h)- ona e métodos in vitro
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
AU2014254052B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP3003313A1 (en) 2013-05-29 2016-04-13 Signal Pharmaceuticals, LLC Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
EA201790189A1 (ru) 2014-07-14 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Способы лечения злокачественного новообразования с использованием замещенных пирролопиримидиновых соединений, композиции на их основе
SMT202100225T1 (it) * 2016-12-20 2021-05-07 Astrazeneca Ab Composti di ammino-triazolopiridina e loro uso nel trattamento del cancro
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
HUE062437T2 (hu) * 2018-03-01 2023-11-28 Essilor Int Lencseelem
BR202019004173Y1 (pt) 2018-03-01 2024-02-20 Essilor International Dispositivo óptico
CN113493471B (zh) * 2020-04-03 2024-06-11 山东轩竹医药科技有限公司 杂芳环类激酶抑制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051493A2 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2008051494A1 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY177695A (en) 2009-10-26 2020-09-23 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051493A2 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2008051494A1 (en) * 2006-10-19 2008-05-02 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2010062571A1 (en) * 2008-10-27 2010-06-03 Signal Pharmaceuticals, Llc Mtor kinase inhibitors for oncology indications and diseases associated with the mtor/p13k/akt pathway
WO2011133668A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ANA S. MARTINS, ET AL.: "Insulin-Like Growth Factor IReceptor Pathway Inhibition byADW742, Alone or in Combinationwith Imatinib,Doxorubicin, orVincristine, Is a Novel Therapeutic Approach in EwingTumor", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH., US, vol. 12, no. 11, 1 June 2006 (2006-06-01), US, pages 3532 - 3540, XP002551195, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-05-1778 *
BALAMUTH, N.J. ; WOMER, R.B.: "Ewing's sarcoma", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 11, no. 2, 1 February 2010 (2010-02-01), AMSTERDAM, NL, pages 184 - 192, XP026884321, ISSN: 1470-2045, DOI: 10.1016/S1470-2045(09)70286-4 *
DANCEY JANET E; MONZON JOSE: "Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies", FUTURE ONCOLOGY, UK, vol. 7, no. 7, 1 July 2011 (2011-07-01), UK, pages 827 - 839, XP009169333, ISSN: 1744-8301, DOI: 10.2217/fon.11.57 *
LORI BERK; MONICA M. MITA; JEFF KREISBERG; CAMILLE L. BEDROSIAN; ANTHONY W. TOLCHER; TIM CLACKSON; VICTOR M. RIVERA: "Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 69, no. 5, 10 January 2012 (2012-01-10), Berlin, DE, pages 1369 - 1377, XP035047366, ISSN: 1432-0843, DOI: 10.1007/s00280-011-1813-7 *
MARK AGULNIK: "New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma", CANCER, ¬JOHN WILEY & SONS| :, vol. 118, no. 6, 15 March 2012 (2012-03-15), pages 1486 - 1497, XP055061618, ISSN: 0008543X, DOI: 10.1002/cncr.26361 *
MITA M M, MITA A C, CHU Q S, ROWINSKY E K, FETTERLY G J, GOLDSTON M, PATNAIK A, MATHEWS L, RICART A D, MAYS T, KNOWLES H, RIVERA V: "Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.", JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, USA, vol. 26, no. 3, 20 January 2008 (2008-01-20), USA, pages 361 - 367, XP002696908, ISSN: 1527-7755, DOI: 10.1200/JCO.2007.12.0345 *
OIKAWA T: "ETS TRANSCRIPTION FACTORS: POSSIBLE TARGETS FOR CANCER THERAPY", CANCER SCIENCE, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 95, no. 08, 1 August 2004 (2004-08-01), JP, pages 626 - 633, XP009039358, ISSN: 1347-9032, DOI: 10.1111/j.1349-7006.2004.tb03320.x *
P. C. HOLLENHORST, M. W. FERRIS, M. A. HULL, H. CHAE, S. KIM, B. J. GRAVES: "Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells", GENES & DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, vol. 25, no. 20, 15 October 2011 (2011-10-15), pages 2147 - 2157, XP055061642, ISSN: 08909369, DOI: 10.1101/gad.17546311 *
R. M. SQUILLACE, D. MILLER, M. COOKSON, S. D. WARDWELL, L. MORAN, D. CLAPHAM, F. WANG, T. CLACKSON, V. M. RIVERA: "Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC., vol. 10, no. 10, 1 October 2011 (2011-10-01), pages 1959 - 1968, XP055061614, ISSN: 15357163, DOI: 10.1158/1535-7163.MCT-11-0273 *
SILVIA MATEO-LOZANO, OSCAR M TIRADO AND VICENTE NOTARIO: "Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation.", ONCOGENE, vol. 22, no. 58, 18 December 2003 (2003-12-18), pages 9282 - 9287, XP002665931, ISSN: 0950-9232, DOI: 10.1038/SJ.ONC.1207081 *
VINCENZI BRUNO; NAPOLITANO ANDREA; D'ONOFRIO LORETTA; FREZZA ANNA MARIA; SILLETTA MARIANNA; VENDITTI OLGA; SANTINI DANIELE; TONINI: "Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside", EXPERT OPINION ON INVESTIGATIONAL DRUGS, INFORMA HEALTHCARE, UNITED KINGDOM, vol. 20, no. 12, 1 December 2011 (2011-12-01), United Kingdom, pages 1685 - 1705, XP009169335, ISSN: 1744-7658, DOI: 10.1517/13543784.2011.628984 *
VIVEK SUBBIAH, AUNG NAING, ROBERT E. BROWN, HELEN CHEN, LAURENCE DOYLE, PATRICIA LORUSSO, ROBERT BENJAMIN, PETE ANDERSON, RAZELLE : "Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, vol. 6, no. 4, 1 January 2011 (2011-01-01), pages e18424 - e18424, XP055061616, ISSN: 19326203, DOI: 10.1371/journal.pone.0018424 *

Also Published As

Publication number Publication date
HK1201755A1 (en) 2015-09-11
IL234640B (en) 2020-05-31
TWI664968B (zh) 2019-07-11
KR20140138929A (ko) 2014-12-04
MX360877B (es) 2018-11-21
US20130245029A1 (en) 2013-09-19
JP2015516375A (ja) 2015-06-11
MY182650A (en) 2021-01-27
MX2014011117A (es) 2015-04-08
TWI600428B (zh) 2017-10-01
CN104302295B (zh) 2017-06-20
AU2013203156C1 (en) 2016-02-18
ES2677908T3 (es) 2018-08-07
IL274318A (en) 2020-06-30
KR102057358B1 (ko) 2019-12-18
TW201733586A (zh) 2017-10-01
AU2013203156A1 (en) 2013-10-03
CN107137402A (zh) 2017-09-08
KR20200034818A (ko) 2020-03-31
TW201343167A (zh) 2013-11-01
CA2867349A1 (en) 2013-09-19
PH12014502048A1 (en) 2014-12-10
AU2013203156B2 (en) 2015-12-10
PH12018502234B1 (en) 2021-07-23
IL234640A0 (en) 2014-11-30
EP2825168A1 (en) 2015-01-21
EP2825168B1 (en) 2018-05-09
BR112014022697A2 (pt) 2020-06-30
SG11201405706TA (en) 2014-10-30
JP6470821B2 (ja) 2019-02-13
NZ628421A (en) 2016-04-29
CN104302295A (zh) 2015-01-21
PH12014502048B1 (en) 2020-10-28
PH12018502234A1 (en) 2019-08-14
EA201491694A1 (ru) 2015-06-30
KR20190058673A (ko) 2019-05-29
WO2013138556A1 (en) 2013-09-19
NI201400109A (es) 2015-01-15
ZA201406709B (en) 2016-07-27
JP2018065820A (ja) 2018-04-26

Similar Documents

Publication Publication Date Title
EA028434B1 (ru) Лечение рака ингибиторами tor киназы
EA028414B1 (ru) Лечение рака ингибиторами tor киназы
EA028062B1 (ru) Лечение рака ингибиторами tor киназы
JP6769982B2 (ja) Ｒａｓ変異と関連するがんの治療方法
KR102790127B1 (ko) Egfr 돌연변이와 관련된 암을 치료하는 조성물 및 방법
EA028462B1 (ru) Способы лечения немелкоклеточного рака легких на поздних стадиях c применением комбинированного лечения с ингибитором киназы tor
US11395821B2 (en) Treatment of EGFR-driven cancer with fewer side effects
EA034512B1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
US20230059381A1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
US20230210859A1 (en) Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
TW202502325A (zh) 治療黑色素瘤的藥物組合的用途
BR112014022707A2 (pt) uso de uma quantidade eficaz de um inibidor de quinase tor, método para melhorar os critérios de avaliação, método para a inibição da fosforilação, método para a inibição da atividade de proteína, método para a medição da inibição da fosforilação, kit
US11040038B2 (en) Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
EP2694073A1 (en) Combinations of akt and mek inhibitor compounds, and methods of use
CN120857931A (zh) 用于治疗患有血液学恶性病的患者的方法
US20260027107A1 (en) Compositions and methods for treating polycythemia
US20170224670A1 (en) Drug Combination to Treat Melanoma
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
US20140296265A1 (en) Method of Treating Lymphoma Using Pyridopyrimidinone Inhibitors of PI3K/mTOR
WO2021175824A1 (en) Method for administration of an anti cancer agent
JP2003277265A (ja) ｅＮＯＳ発現に起因する疾患の予防または治療薬
US20210121460A1 (en) A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor
CN104271140B (zh) I型和ii型糖尿病的治疗
US9763944B2 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
JP4522261B2 (ja) ブドウ膜黒色腫の処置

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU